# VTRS catalysts: Viatris Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vtrs/catalysts

> Viatris Inc (VTRS) has 14 upcoming catalysts. The next is the mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Viatris Inc |
| Ticker | VTRS (Nasdaq) |
| SEC CIK | 1792044 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vtrs |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 27, 2015 | [Acetaminophen (acetaminophen) complete response letter (CRL)](https://sec-api.dev/pdufa/acetaminophen) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206610_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| March 10, 2016 | [Acetaminophen (acetaminophen) complete response letter (CRL)](https://sec-api.dev/pdufa/acetaminophen) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206610_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| February 1, 2017 | [Acetaminophen (acetaminophen) complete response letter (CRL)](https://sec-api.dev/pdufa/acetaminophen) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206610_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| December 1, 2017 | [Ogivri (trastuzumab-dkst) FDA approval](https://sec-api.dev/pdufa/trastuzumab-dkst) | VTRS |  | completed, approved | "BLA761074 ORIG-1: submission_status AP, submission_status_date 20171201, review_priority STANDARD; sponsor_name MYLAN GMBH; product OGIVRI (TRASTUZUMAB-DKST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761074%22)) |
| December 6, 2017 | [Acetaminophen (acetaminophen) complete response letter (CRL)](https://sec-api.dev/pdufa/acetaminophen) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206610_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| February 5, 2018 | [Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate) FDA approval](https://sec-api.dev/pdufa/efavirenz-lamivudine-tenofovir-disoproxil) | VTRS |  | completed, approved | "NDA208255 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180205, review_priority PRIORITY; sponsor_name MYLAN; product SYMFI LO (EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208255%22)) |
| February 28, 2018 | [Cimduo (lamivudine; tenofovir disoproxil fumarate) FDA approval](https://sec-api.dev/pdufa/lamivudine-tenofovir-disoproxil) | VTRS |  | completed, approved | "NDA022141 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20180228, review_priority PRIORITY; sponsor_name MYLAN LABS LTD; product CIMDUO (LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022141%22)) |
| March 22, 2018 | [Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate) FDA approval](https://sec-api.dev/pdufa/efavirenz-lamivudine-tenofovir-disoproxil) | VTRS |  | completed, approved | "NDA022142 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20180322, review_priority PRIORITY; sponsor_name MYLAN LABS LTD; product SYMFI (EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022142%22)) |
| May 17, 2018 | [Nda210605 complete response letter (CRL)](https://sec-api.dev/pdufa/nda210605) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210605_2020_Orig1s000OtherActionLtrs.pdf%22)) |
| June 4, 2018 | [Fulphila (pegfilgrastim-jmdb) FDA approval](https://sec-api.dev/pdufa/pegfilgrastim-jmdb) | VTRS |  | completed, approved | "BLA761075 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180604, review_priority STANDARD; sponsor_name MYLAN GMBH; product FULPHILA (PEGFILGRASTIM-JMDB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761075%22)) |
| July 10, 2018 | [Vancomycin Hydrochloride (vancomycin) FDA approval](https://sec-api.dev/pdufa/vancomycin) | VTRS |  | completed, approved | "NDA209481 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180710, review_priority STANDARD; sponsor_name MYLAN LABS LTD; product VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209481%22)) |
| November 9, 2018 | [Yupelri (revefenacin) FDA approval](https://sec-api.dev/pdufa/revefenacin) | VTRS |  | completed, approved | "NDA210598 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181109, review_priority STANDARD; sponsor_name MYLAN IRELAND LTD; product YUPELRI (REVEFENACIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210598%22)) |
| June 6, 2019 | [Acetaminophen (acetaminophen) complete response letter (CRL)](https://sec-api.dev/pdufa/acetaminophen) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206610_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| August 6, 2019 | [Epzicom (abacavir sulfate; lamivudine) complete response letter (CRL)](https://sec-api.dev/pdufa/abacavir-lamivudine) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22204311_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| August 14, 2019 | [Pretomanid (pretomanid) FDA approval](https://sec-api.dev/pdufa/pretomanid) | VTRS |  | completed, approved | "NDA212862 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190814, review_priority PRIORITY; sponsor_name MYLAN IRELAND LTD; product PRETOMANID (PRETOMANID)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212862%22)) |
| August 28, 2019 | [Nda210605 complete response letter (CRL)](https://sec-api.dev/pdufa/nda210605) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210605_2020_Orig1s000OtherActionLtrs.pdf%22)) |
| June 11, 2020 | [Semglee (insulin glargine) FDA approval](https://sec-api.dev/pdufa/insulin-glargine) | VTRS |  | completed, approved | "BLA210605 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200611, review_priority STANDARD; sponsor_name MYLAN PHARMS INC; product SEMGLEE (INSULIN GLARGINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA210605%22)) |
| July 6, 2020 | [Hulio (adalimumab-fkjp) FDA approval](https://sec-api.dev/pdufa/adalimumab-fkjp) | VTRS |  | completed, approved | "BLA761154 ORIG-1: submission_status AP, submission_status_date 20200706, review_priority STANDARD; sponsor_name MYLAN PHARMS INC; product HULIO (ADALIMUMAB-FKJP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761154%22)) |
| July 28, 2021 | [Semglee (insulin glargine-yfgn) FDA approval](https://sec-api.dev/pdufa/insulin-glargine-yfgn) | VTRS |  | completed, approved | "BLA761201 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20210728, review_priority STANDARD; sponsor_name MYLAN PHARMS INC; product SEMGLEE (INSULIN GLARGINE-YFGN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761201%22)) |
| January 28, 2022 | [Geodon (ziprasidone hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ziprasidone) | VTRS |  | completed, approved | "NDA020825 SUPPL-63 (Efficacy): submission_status AP, submission_status_date 20220128, review_priority STANDARD; sponsor_name VIATRIS; product GEODON (ZIPRASIDONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020825%22)) |
| April 29, 2022 | [Ermeza (levothyroxine sodium) FDA approval](https://sec-api.dev/pdufa/levothyroxine) | VTRS |  | completed, approved | "NDA215809 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220429, review_priority STANDARD; sponsor_name MYLAN; product ERMEZA (LEVOTHYROXINE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215809%22)) |
| July 14, 2022 | [Hulio (adalimumab-fkjp) label expansion decision](https://sec-api.dev/pdufa/adalimumab-fkjp) | VTRS |  | completed, approved | "BLA761154 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220714, review_priority STANDARD; sponsor_name MYLAN PHARMS INC; product HULIO (ADALIMUMAB-FKJP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761154%22)) |
| January 13, 2023 | [Epzicom (abacavir sulfate; lamivudine) complete response letter (CRL)](https://sec-api.dev/pdufa/abacavir-lamivudine) | VTRS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22204311_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| January 31, 2023 | [Revatio® (sildenafil) label expansion decision](https://sec-api.dev/pdufa/sildenafil) | VTRS |  | completed, approved | "NDA021845 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230131, review_priority STANDARD; sponsor_name VIATRIS; product REVATIO (SILDENAFIL CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021845%22)) |
| March 3, 2023 | [Revatio® (sildenafil) label expansion decision](https://sec-api.dev/pdufa/sildenafil) | VTRS |  | completed, approved | "NDA203109 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name VIATRIS; product REVATIO (SILDENAFIL CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203109%22)) |
| June 26, 2024 | [Vancomycin Hydrochloride (vancomycin) label expansion decision](https://sec-api.dev/pdufa/vancomycin) | VTRS |  | completed, approved | "NDA209481 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20240626, review_priority N/A; sponsor_name MYLAN LABS LTD; product VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209481%22)) |
| November 22, 2024 | [Pretomanid (pretomanid) label expansion decision](https://sec-api.dev/pdufa/pretomanid) | VTRS |  | completed, approved | "NDA212862 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241122, review_priority STANDARD; sponsor_name MYLAN IRELAND LTD; product PRETOMANID (PRETOMANID)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212862%22)) |
| December 23, 2024 | [Arixtra (fondaparinux sodium) label expansion decision](https://sec-api.dev/pdufa/fondaparinux) | VTRS |  | completed, approved | "NDA021345 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20241223, review_priority STANDARD; sponsor_name MYLAN IRELAND LTD; product ARIXTRA (FONDAPARINUX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021345%22)) |
| February 27, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000004/exhibit991-4q24earningsrel.htm)) |
| May 8, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000016/exhibit991-1q25earningsrel.htm)) |
| August 7, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000031/exhibit991-2q25earningsrel.htm)) |
| late 2025 | [MR-107A NDA/BLA submission](https://sec-api.dev/pdufa/mr-107a) | VTRS |  | scheduled | "The Company is targeting to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000016/exhibit991-1q25earningsrel.htm)) |
| November 6, 2025 | [Viatris Inc FDA approval](https://sec-api.dev/companies/vtrs/catalysts) | VTRS | iron deficiency anemia in adult and pediatric patients | completed, approved | "•Iron Sucrose Injection: The Company announced that the FDA approved its Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients (2 years of age and older) with chronic kidney disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/exhibit991-3q25earningsrel.htm)) |
| November 6, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/exhibit991-3q25earningsrel.htm)) |
| Dec 2025 | [Viatris Inc NDA/BLA acceptance](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "•In December 2025, the Company announced that the FDA accepted for review the New Drug Application (NDA) for the Company's investigational low-dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol) for contraception." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| February 23, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| February 23, 2026 | [MR-141 NDA/BLA acceptance](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | completed | "•In February 2026, the Company announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| May 7, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports First-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000025/exhibit991-1q26earningsrel.htm)) |
| July 28, 2026 | [Gwyn Lo (ethinyl estradiol; norelgestromin) FDA approval](https://sec-api.dev/pdufa/ethinyl-estradiol-norelgestromin) | VTRS |  | completed, approved | "NDA219990 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260728, review_priority STANDARD; sponsor_name VIATRIS SPECIALTY; product GWYN LO (ETHINYL ESTRADIOL; NORELGESTROMIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219990%22)) |
| July 30, 2026 | [INPEFA® (sotagliflozin) PDUFA date](https://sec-api.dev/pdufa/sotagliflozin) | VTRS |  | scheduled | "the NDA for the Company's investigational low dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol) for contraception was accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a PDUFA goal date of July 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| August 6, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Second-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| August 6, 2026 | [Viatris Inc FDA approval](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed, approved | "•In July, the Company announced that the U.S. Food and Drug Administration (FDA) approved Gwyn LoTM (norelgestromin and ethinyl estradiol transdermal system), a new combined hormonal contraceptive patch with low-dose estrogen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| October 17, 2026 | [MR-141 PDUFA date](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | scheduled | "the FDA has assigned a PDUFA goal date of October 17, 2026 for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| Nov 2026 to Feb 2027 | [Mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn) topline data readout](https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn) | VTRS | Contraception | scheduled | "NCT07365904 (Investigating Ovulation Inhibition for Use as a Contraceptive): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365904)) |
| November 5, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Third-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |
| November 5, 2026 | [RYZUMVI (ryzumvi) FDA approval](https://sec-api.dev/pdufa/ryzumvi) | VTRS | presbyopia in adults | completed, approved | "•In October, the Company announced that the FDA approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |
| November 2026 | [Mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn) primary completion](https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn) | VTRS | Contraception | scheduled | "NCT07365904 (Investigating Ovulation Inhibition for Use as a Contraceptive): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365904)) |
| Dec 2026 to Mar 2027 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| December 27, 2026 | [MR-107A PDUFA date](https://sec-api.dev/pdufa/mr-107a) | VTRS | moderate-to-severe acute pain | scheduled | "in May, the Company announced that the FDA accepted for review the New Drug Application for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain and the FDA has assigned a PDUFA goal date of December 27, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| December 2026 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| Mar to Jun 2027 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05648500 (A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648500)) |
| March 2027 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05648500 (A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648500)) |
| May 2027 | [Transdermal system containing progestin primary completion](https://sec-api.dev/pdufa/transdermal-system-containing-progestin) | VTRS | Female Contraception | scheduled | "NCT06672016 (Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672016)) |
| May to Aug 2027 | [Transdermal system containing progestin topline data readout](https://sec-api.dev/pdufa/transdermal-system-containing-progestin) | VTRS | Female Contraception | scheduled | "NCT06672016 (Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672016)) |
| July 2027 | [Selatogrel primary completion](https://sec-api.dev/pdufa/selatogrel) | VTRS | Acute Myocardial Infarction | scheduled | "NCT04957719 (Selatogrel Outcome Study in Suspected Acute Myocardial Infarction): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04957719)) |
| Jul to Oct 2027 | [Selatogrel topline data readout](https://sec-api.dev/pdufa/selatogrel) | VTRS | Acute Myocardial Infarction | scheduled | "NCT04957719 (Selatogrel Outcome Study in Suspected Acute Myocardial Infarction): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04957719)) |
| Oct 2027 to Jan 2028 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | SLE - Systemic Lupus Erythematosus | scheduled | "NCT07266090 (A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor Viatris Pharmaceuticals Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266090)) |
| October 2027 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | SLE - Systemic Lupus Erythematosus | scheduled | "NCT07266090 (A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor Viatris Pharmaceuticals Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266090)) |
| August 2029 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Nephritis, Lupus; Lupus Erythematosus, Systemic | scheduled | "NCT07201129 (A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07201129)) |
| Aug to Nov 2029 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Nephritis, Lupus; Lupus Erythematosus, Systemic | scheduled | "NCT07201129 (A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07201129)) |

## Drugs

- [Acetaminophen (acetaminophen)](https://sec-api.dev/pdufa/acetaminophen): 
- [Hulio (adalimumab-fkjp)](https://sec-api.dev/pdufa/adalimumab-fkjp): 
- [Cenerimod 4 mg](https://sec-api.dev/pdufa/cenerimod): SLE - Systemic Lupus Erythematosus, Nephritis, Lupus, Lupus Erythematosus, Systemic
- [Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate)](https://sec-api.dev/pdufa/efavirenz-lamivudine-tenofovir-disoproxil): 
- [Gwyn Lo (ethinyl estradiol; norelgestromin)](https://sec-api.dev/pdufa/ethinyl-estradiol-norelgestromin): 
- [Arixtra (fondaparinux sodium)](https://sec-api.dev/pdufa/fondaparinux): 
- [Semglee (insulin glargine)](https://sec-api.dev/pdufa/insulin-glargine): 
- [Semglee (insulin glargine-yfgn)](https://sec-api.dev/pdufa/insulin-glargine-yfgn): 
- [Cimduo (lamivudine; tenofovir disoproxil fumarate)](https://sec-api.dev/pdufa/lamivudine-tenofovir-disoproxil): 
- [Ermeza (levothyroxine sodium)](https://sec-api.dev/pdufa/levothyroxine): 
- [MR-107A](https://sec-api.dev/pdufa/mr-107a): moderate-to-severe acute pain
- [Mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn)](https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn): Contraception
- [MR-141](https://sec-api.dev/pdufa/mr-141): presbyopia
- [Nda210605](https://sec-api.dev/pdufa/nda210605): 
- [Fulphila (pegfilgrastim-jmdb)](https://sec-api.dev/pdufa/pegfilgrastim-jmdb): 
- [Pretomanid (pretomanid)](https://sec-api.dev/pdufa/pretomanid): 
- [Yupelri (revefenacin)](https://sec-api.dev/pdufa/revefenacin): 
- [Selatogrel](https://sec-api.dev/pdufa/selatogrel): Acute Myocardial Infarction
- [Revatio® (sildenafil)](https://sec-api.dev/pdufa/sildenafil): 
- [Transdermal system containing progestin](https://sec-api.dev/pdufa/transdermal-system-containing-progestin): Female Contraception
- [Ogivri (trastuzumab-dkst)](https://sec-api.dev/pdufa/trastuzumab-dkst): 
- [Vancomycin Hydrochloride (vancomycin)](https://sec-api.dev/pdufa/vancomycin): high-risk of cdi
- [Geodon (ziprasidone hydrochloride)](https://sec-api.dev/pdufa/ziprasidone): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vtrs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VTRS catalysts: Viatris Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vtrs/catalysts

```bibtex
@misc{secapidev_companies_vtrs_catalysts_20261116,
  title        = {VTRS catalysts: Viatris Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vtrs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vtrs_catalysts_20261116","title":"VTRS catalysts: Viatris Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vtrs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
